# A Study of RD06-04 in Patients With Active Autoimmune Diseases

> **NCT06548620** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Nanjing Bioheng Biotech Co., Ltd.**

## Conditions studied

- SLE
- Sclerosis
- ANCA Associated Vasculitis
- IIM
- SS
- MS
- NMO Spectrum Disorder
- MG

## Interventions

- **DRUG:** RD06-04 cell infusion

## Key facts

- **NCT ID:** NCT06548620
- **Lead sponsor:** Nanjing Bioheng Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** R\&D strategy adjustment
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548620, "A Study of RD06-04 in Patients With Active Autoimmune Diseases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06548620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*